A new white paper, ‘The Resilience Imperative: Reinventing healthcare supply chains’, commissioned by DHL, the world’s leading logistics company, argues global life sciences and healthcare (LSH) companies must reevaluate and revolutionise their approach to their supply chain management in order to survive the unprecedented myriad of challenges threatening major disruption to the industry.
This thought leadership paper identifies a number of key trends which could derail the industry’s logistics such as emerging market growth, burgeoning regulatory and compliance requirements, changing product characteristics, and rocketing counterfeit drug trafficking. Moreover, shrinking margins, escalating cost pressures and growing consumerism are transforming the business paradigm. What is emerging is a business model that looks and acts like the consumer goods industry, where the customer – not the manufacturer – holds the power.
Lisa Harrington, President of the lharrington group LLC, prepared the report in collaboration with DHL to identify the challenges and developments affecting the sector globally. Harrington is also Associate Director of the Supply Chain Management Center and lecturer of supply chain management at the Robert H. Smith School of Business, University of Maryland.
She says, “The stakes in the new normal of LSH are enormous. So large, in fact, that the U.S. Congress was willing to shut down the entire US federal government for two weeks while it fought over healthcare reform issues. That shutdown, according to Standard and Poor’s, cost the US economy more than $24 billion.
“The LSH sector finds itself in the position of needing to rethink its entire economic model, and find ways to reduce costs across the board, in order to maintain share in a marketplace that is no longer willing, or able, to fund previous pricing.
“The old LSH supply chain model is no longer fit for purpose. The new LSH environment requires a more resilient, adaptive supply chain model that delivers robust global management capabilities, reduces costs and hard-wires the agility, flexibility and resiliency needed to support the challenges of global health.”
For most industries, experiencing two or three complex challenges at one time is enough to cause turbulence. But the LSH sector is contending with a complex web of issues which amount to the end of business as usual and call for a corresponding change in supply chain management:
Patent cliff, changing products and profit erosion: In 2012, $38bn of sales was lost due to patent expiration on major drugs moving to generics, while the global austerity of from value-driven governments, commissioning bodies and private payers worldwide has contributed to prescription sales falling by 1.6% to $714 billion.
A highly cost-effective supply chain that also delivers fast, reliable speed is required to meet the needs of an increasingly empowered, consumer-led market. Meanwhile, higher value products that are better protected from sales erosion carry significant financial risk if mismanaged in the supply chain.
These include biological pharmaceuticals focused on unmet medical needs or medical devices with proven clinical benefits which have complex ranges, temperature requirements and final destinations (including hospitals and to home).
Emerging markets, demographic shifts and healthcare policy: The world’s population is ageing with over 60s expected to be more than 1/3 by 2050. In addition, emerging markets such as Brazil, Russia, India, China and Mexico and their growing middle-classes represent a significant growth opportunity for LSH companies.
To adapt, LSH companies must adopt business models which allow for geographical range and therefore require tailored supply chains that deliver a higher volume of goods to increasingly diverse end points such as hospitals and distributed care in the home.
Regulations, compliance and product integrity: The growing issue of counterfeits has led to regulators enforcing stringent and diverse product integrity control. Intensified security and data collection adds pressure throughout the supply chain, as rigorous serialisation is required at distribution touch point, often painstakingly at the unit rather than lot level.
Jonathan Blamey, VP LSH, DHL Supply Chain, says, “Providing life-saving products is a big responsibility, one with risks that far outweigh those in a typical supply chain environment. LSH companies have to configure their business for each market, meeting the regulatory requirements and operational constraints of each healthcare system. Add in manufacturing constraints, compliance, temperature control and other factors, and you get a highly complex supply chain.
“To capitalise on growth opportunities and prosper in this environment, there is a tremendous opportunity and pressing need for LSH companies to take learnings from other supply chain models such as the automotive and FMCG industries. We understand the challenges facing LSH companies and have created solutions that help our customers to meet today’s challenges and anticipate tomorrow’s.”
DHL Supply Chain has expanded its global network of LSH services by over 25% in 2013 with the addition of 30 new warehouses, of which 12 are in emerging markets. It now operates over 150 facilities comprising over 2 million square metres of warehousing space and 1.9 million pallet locations dedicated to LSH, with over 4500 dedicated healthcare staff worldwide.
Download and view the full report at
www.dhl.com/lifesciences-resilience. For more information about supply chain best practice, solutions and success stories, visit the DHL Supply Chain LSH pages at www.dhl.co.uk/en/logistics/industry_sector_solutions/life_sciences_and_healthcare_logistics.html.
